CAS |
No.103766-25-2 |
中文名称 |
吉莫斯特 |
英文名称 |
Gimeracil |
别名 |
;吉莫斯特;吉莫斯特(CDHP);5-氯-4-羟基-2(1H)-吡啶酮;吉美嘧啶;4-羟基-5-氯-2-(1H)吡啶酮; |
分子式 |
C5H4ClNO2 |
分子量 |
145.54 |
溶解性 |
Soluble in DMSO ≥2mg/mL(Need ultrasonic) |
纯度 |
≥98% |
外观(性状) |
White to brown Solid |
储存条件 |
Powder:2-8℃,2 years;Insolvent(母液):-20℃,6 months;-80℃,1 year |
运输条件 |
冷藏运输 |
EC |
EINECS 1312995-182-4 |
MDL |
MFCD08458352 |
SMILES |
O=C1C=C(O)C(Cl)=CN1 |
靶点 |
Others |
通路 |
Others |
背景说明 |
是二氢嘧啶脱氢酶 (DPYD) 的有效抑制剂,可抑制 DNA 双链断裂修复同源重组的早期步骤。 |
生物活性 |
Gimeracil, a component of an oral fluoropyrimidine derivative S-1, inhibits DNA DSB repair and is a potent inhibitor of DPYD (dihydropyrimidine dehydrogenase, DPD)[1][2]. |
In Vitro |
Results of gamma-H2AX focus assay indicated that Gimeracil inhibited DNA DSB repair. It did not sensitize cells deficient in HR but sensitized those deficient in NHEJ. In SCneo assay, Gimeracil reduced the frequency of neo-positive clones. Additionally, it sensitized the cells in S-phase more than in G0/G1.Gimeracil inhibits HR. Gimeracil may enhance the efficacy of radiotherapy through the suppression of HR-mediated DNA repair pathways.[1]Gimeracil pretreatment significantly restrains the formation of radiation-induced foci of Rad51 and RPA, whereas it increased the number of foci of Nbs1, Mre11, Rad50, and FancD2[2]. |
细胞实验 |
Used various cell lines deficient in non-homologous end-joining (NHEJ) or homologous recombination (HR) as well as DLD-1 and HeLa in clonogenic assay. gamma-H2AX focus formation and SCneo assay was performed to examine the effects of Gimeracil on DNA double strand break (DSB) repair mechanisms.[1] |
数据来源文献 |
[1]. Masaru Takagi, et al. Gimeracil sensitizes cells to radiation via inhibition of homologous recombination. Radiother Oncol. 2010 Aug;96(2):259-66.
[2]. Koh-Ichi Sakata, et al. Gimeracil, an inhibitor of dihydropyrimidine dehydrogenase, inhibits the early step in homologous recombination. Cancer Sci. 2011 Sep;102(9):1712-6. |
规格 |
25mg 50mg 100mg 500mg |
单位 |
瓶 |